PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5

Leukemia

Volumn 27, Issue 4, 2013, Pages 992-995

  Fazio, G ^a   Cazzaniga, V ^a   Palmi, C ^a   Galbiati, M ^a   Giordan, M ^b   Te Kronnie, G ^b   Rolink, A ^c   Biondi, A ^a   Cazzaniga, G ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX5;

ANIMAL CELL; CELL ADHESION; DOWN REGULATION; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; LETTER; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; GENE EXPRESSION PROFILING; HUMANS; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS;

EID: 84876139733     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.281     Document Type: Letter

References (14)

1. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007; 8: 463-470.
2. Fazio G, Biondi A, Cazzaniga G (eds). The role of PAX5 in ALL. In: Novel Aspects in Acute Lymphoblastic Leukemia. InTech, 2011.
3. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
4. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009; 23: 134-143.
5. Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 2008; 68: 181-189.
6. Kawamata N, Ogawa S, Zimmermann M, Kato M, Sanada M, Hemminki K et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by highresolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008; 111: 776-784.
7. Kawamata N, Pennella MA, Woo JL, Berk AJ, Koeffler HP. Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene 2012; 31: 966-977.
8. Rolink AG, Schaniel C, Melchers F. Stability and plasticity of wild-type and Pax5-deficient precursor B cells. Immunol Rev 2002; 187: 87-95.
9. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 2006; 24: 269-281.
10. McManus S, Ebert A, Salvagiotto G, Medvedovic J, Sun Q, Tamir I et al. The transcription factor Pax5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cells. EMBO J 2011; 30: 2388-2404.
11. Pridans C, Holmes ML, Polli M, Wettenhall JM, Dakic A, Corcoran LM et al. Identification of Pax5 target genes in early B cell differentiation. J Immunol 2008; 180: 1719-1728.
12. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 2007; 27: 49-63.
13. Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 2007; 13: 313-316.
14. Boily G, Larose J, Langlois S, Sinnett D. Identification of transcripts modulated by ETV6 expression. Br J Haematol 2007; 136: 48-62.